Due to recent concerns about MACE and cancer associated with JAKi drugs,22 any cessations of ADA or TOF due to an adverse event are described in eResults 6 in Supplement 1 for all eligible patients (n = 842) and patients who had been excluded due to missing data on the components of the DAS28-CRP (n = 326). This evidence concerns the gene CRP and cancer.